---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-012143"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:27:17.205564+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical reports record FY 2023 revenue $91.3M, up 58% YoY; guides FY 2024 $112M-$116M

## Summary
- FY 2023 revenue $91.3M, +58% YoY; organic growth 15%.
- Net income $0.7M ($0.01/share) vs net loss $8.5M ($0.09) in 2022.
- Non-GAAP adjusted EBITDA $1.0M in 2023, compared to loss of $3.0M in 2022.
- FY 2024 revenue guidance $112M-$116M, representing 23%-27% growth.
- Gross margin improved 540 bps to 60.8% for 2023.

## SEC filing metadata
- accession: 0001493152-24-012143
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315224012143/0001493152-24-012143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315224012143/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-012143
- JSON: https://secwatch.observer/filing/0001493152-24-012143.json
- Plain text: https://secwatch.observer/filing/0001493152-24-012143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.